Detalhe da pesquisa
1.
Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma.
Blood
; 137(26): 3616-3628, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33763699
2.
Outcome of carfilzomib/pomalidomide-based regimens after daratumumab-based treatment in relapsed multiple myeloma: A Canadian Myeloma Research Group Database analysis.
Eur J Haematol
; 111(5): 815-823, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37574220
3.
Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma.
J Oncol Pharm Pract
; 29(5): 1172-1177, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-36067063
4.
Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients.
Br J Cancer
; 126(5): 718-725, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34802051
5.
Outcomes of daratumumab in the treatment of multiple myeloma: A retrospective cohort study from the Canadian Myeloma Research Group Database.
Br J Haematol
; 198(1): 93-102, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35383886
6.
Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma.
Haematologica
; 107(10): 2408-2417, 2022 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35354247
7.
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics.
Eur J Haematol
; 108(1): 73-83, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34496096
8.
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.
Lancet
; 396(10262): 1563-1573, 2020 11 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-33189178
9.
Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR.
Blood
; 133(2): 147-155, 2019 01 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30478094
10.
Medical and mental health implications of gestational surrogacy.
Am J Obstet Gynecol
; 225(3): 264-269, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33839094
11.
Retrospective study of treatment patterns and outcomes post-lenalidomide for multiple myeloma in Canada.
Eur J Haematol
; 107(4): 416-427, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34129703
12.
The impact of lenalidomide maintenance on second-line chemotherapy in transplant eligible patients with multiple myeloma.
Eur J Haematol
; 106(5): 673-681, 2021 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33539037
13.
Weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed/refractory multiple myeloma: Final results from the MCRN-003/MYX.1 single arm phase II trial.
Am J Hematol
; 96(5): 552-560, 2021 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33650179
14.
Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma.
Blood
; 132(24): 2546-2554, 2018 12 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-30352784
15.
Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma.
Blood
; 131(3): 301-310, 2018 01 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-29150421
16.
Chronic Conjunctivitis From a Retained Contact Lens.
Eye Contact Lens
; 46(1): e1-e4, 2020 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-30724838
17.
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Lancet Oncol
; 20(6): 781-794, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31097405
18.
Low-depth sequencing for copy number abnormalities in multiple myeloma supersedes fluorescent in situ hybridization in scope and resolution.
Clin Genet
; 96(2): 163-168, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31066036
19.
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
N Engl J Med
; 373(7): 621-31, 2015 Aug 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-26035255
20.
Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX.
Haematologica
; 103(12): 2088-2096, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30237262